Nisha Nanda

1.8k total citations · 1 hit paper
33 papers, 1.4k citations indexed

About

Nisha Nanda is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Nisha Nanda has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Genetics. Recurrent topics in Nisha Nanda's work include Platelet Disorders and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Nisha Nanda is often cited by papers focused on Platelet Disorders and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Nisha Nanda collaborates with scholars based in United States, Australia and France. Nisha Nanda's co-authors include Robert M. Graham, Siiri E. Iismaa, Ahsan Husain, Fabienne Mackay, W. Andrew Owens, David R. Phillips, Jennifer A. Low, Robert C. Doebele, Brian B. Tuch and Karl R. Clauser and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Nisha Nanda

33 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

2015 302 citations Robert C. Doebele, Lara E. Davis et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nisha Nanda United States	14	561	444	286	235	213	33	1.4k
Koshi Fujikawa Japan	16	240 0.4×	454 1.0×	854 3.0×	290 1.2×	293 1.4×	41	1.7k
Yacine Boulaftali France	23	318 0.6×	830 1.9×	421 1.5×	188 0.8×	226 1.1×	47	1.7k
Barbara Hertel Germany	12	171 0.3×	210 0.5×	504 1.8×	194 0.8×	122 0.6×	14	1.0k
Raphaël Thuillet France	17	909 1.6×	118 0.3×	318 1.1×	110 0.5×	121 0.6×	42	1.3k
Masamichi Shiraga Japan	23	159 0.3×	877 2.0×	401 1.4×	103 0.4×	254 1.2×	44	1.6k
Anne Zufferey Switzerland	16	167 0.3×	722 1.6×	317 1.1×	103 0.4×	151 0.7×	24	1.3k
Bernardo Garicochea Brazil	19	195 0.3×	358 0.8×	410 1.4×	381 1.6×	287 1.3×	67	1.4k
Tatsuru Ikeda Japan	17	310 0.6×	212 0.5×	306 1.1×	216 0.9×	158 0.7×	56	1.2k
M Keeton United States	10	167 0.3×	495 1.1×	432 1.5×	92 0.4×	101 0.5×	13	1.3k
Allison C. Ostriker United States	16	197 0.4×	522 1.2×	948 3.3×	105 0.4×	373 1.8×	20	1.9k

Countries citing papers authored by Nisha Nanda

Since Specialization

Citations

This map shows the geographic impact of Nisha Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nisha Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nisha Nanda more than expected).

Fields of papers citing papers by Nisha Nanda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nisha Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nisha Nanda. The network helps show where Nisha Nanda may publish in the future.

Co-authorship network of co-authors of Nisha Nanda

This figure shows the co-authorship network connecting the top 25 collaborators of Nisha Nanda. A scholar is included among the top collaborators of Nisha Nanda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nisha Nanda. Nisha Nanda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hong, David S., Afshin Dowlati, Howard A. Burris, et al.. (2017). Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. European Journal of Cancer. 72. S148–S148. 10 indexed citations

Hong, David S., Afshin Dowlati, Howard A. Burris, et al.. (2016). 150O Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Annals of Oncology. 27. ix46–ix46. 1 indexed citations

Roberts, Kathryn G., Olga A. Bridges, Laura J. Janke, et al.. (2016). Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia. Blood. 128(22). 278–278. 3 indexed citations

Doebele, Robert C., Lara E. Davis, Aria Vaishnavi, et al.. (2015). An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discovery. 5(10). 1049–1057. 302 indexed citations breakdown →

Hong, David S., Marcia S. Brose, Robert C. Doebele, et al.. (2015). Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Molecular Cancer Therapeutics. 14(12_Supplement_2). PR13–PR13. 12 indexed citations

Burris, Howard A., Alice T. Shaw, Todd M. Bauer, et al.. (2015). Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update. Cancer Research. 75(15_Supplement). 4529–4529. 11 indexed citations

Brandhuber, Barbara J., Nisha Nanda, Julia Haas, et al.. (2015). Abstract B192: Identification and characterization of highly potent and selective RET kinase inhibitors for the treatment of RET-driven cancers. Molecular Cancer Therapeutics. 14(12_Supplement_2). B192–B192. 5 indexed citations

Nanda, Nisha, Tim Fennell, & Jennifer A. Low. (2015). Identification of tropomyosin kinase receptor (TRK) mutations in cancer.. Journal of Clinical Oncology. 33(15_suppl). 1553–1553. 7 indexed citations

Cortes, Jörge E., Franck E. Nicolini, Meir Wetzler, et al.. (2013). Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. Clinical Lymphoma Myeloma & Leukemia. 13(5). 584–591. 39 indexed citations

10.

Cortes, Jörge E., Jeff H. Lipton, Delphine Réa, et al.. (2012). Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 120(13). 2573–2580. 89 indexed citations

11.

Nemunaitis, John, Alain C. Mita, Joe Stephenson, et al.. (2012). Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemotherapy and Pharmacology. 71(1). 35–41. 36 indexed citations

12.

Reilly, Michael P., Uma Sinha, Scott M. Taylor, et al.. (2010). PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. 117(7). 2241–2246. 100 indexed citations

13.

Nanda, Nisha & David R. Phillips. (2006). Novel targets for antithrombotic drug discovery. Blood Cells Molecules and Diseases. 36(2). 228–231. 14 indexed citations

14.

Nanda, Nisha, Ming Bao, Karl R. Clauser, et al.. (2005). Platelet Endothelial Aggregation Receptor 1 (PEAR1), a Novel Epidermal Growth Factor Repeat-containing Transmembrane Receptor, Participates in Platelet Contact-induced Activation. Journal of Biological Chemistry. 280(26). 24680–24689. 103 indexed citations

15.

Bailey, Craig D. C., Robert M. Graham, Nisha Nanda, Peter J. Davies, & Gail V.W. Johnson. (2004). Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases. Molecular and Cellular Neuroscience. 25(3). 493–503. 25 indexed citations

16.

Johnson, Kristen, Deborah Van Etten, Nisha Nanda, Robert M. Graham, & Robert Terkeltaub. (2003). Distinct Transglutaminase 2-independent and Transglutaminase 2-dependent Pathways Mediate Articular Chondrocyte Hypertrophy. Journal of Biological Chemistry. 278(21). 18824–18832. 70 indexed citations

17.

Nanda, Nisha, et al.. (2001). Targeted inactivation of G(h)/tissue transglutaminase II. Journal of Biological Chemistry. 276(23). 12 indexed citations

18.

Nanda, Nisha, Siiri E. Iismaa, W. Andrew Owens, et al.. (2001). Targeted Inactivation of Gh/Tissue Transglutaminase II. Journal of Biological Chemistry. 276(23). 20673–20678. 239 indexed citations

19.

Iismaa, Siiri E., Mingjie Wu, Nisha Nanda, W. Bret Church, & Robert M. Graham. (2000). GTP Binding and Signaling by Gh/Transglutaminase II Involves Distinct Residues in a Unique GTP-binding Pocket. Journal of Biological Chemistry. 275(24). 18259–18265. 86 indexed citations

20.

Nanda, Nisha, Siiri E. Iismaa, Neal G. Copeland, et al.. (1999). Organization and Chromosomal Mapping of Mouse Gh/Tissue Transglutaminase Gene (Tgm2). Archives of Biochemistry and Biophysics. 366(1). 151–156. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact